UK-based AI and machine learning firm PinPoint has raised more than £1 million to develop a test designed to rule out cancer in the early stages and save millions for the NHS in unnecessary testing.

Life Technologies acquired Pinpoint Genomics and its early-stage non-small-cell lung cancer test. The test is designed to identify early-stage patients at high risk for progression to late-stage ...

Thank you for signing up! Did you know with a Digital subscription to Yorkshire Post, you can get access to all of our premium content, as well as benefiting from fewer ads, loyalty rewards and much ...

An inexpensive, fast accurate DNA test that reveals a person's risk of developing certain diseases is expected to become a reality, thanks to new technology. An inexpensive, fast, accurate DNA test ...

CARLSBAD, Calif., July 25, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer ...

When a cell dies in a tumor, a growing fetus or elsewhere in the body, bits and pieces of its DNA enter the bloodstream. A new test that identifies the source of such DNA could make it easier to find ...

Colon cancer is one of the top three deadliest forms of cancer - in part because it's often diagnosed so late. Now a groundbreaking study could pinpoint the disease easier, and earlier. The ...

PREGNANT women often anxiously wait weeks for the moment their waters break. But a new blood test could one day pinpoint when a woman will go into labour up to a month before she is due. Please ...